Antibody Firm Affomix Readies to Launch Service Biz in the Summer; Technology for PTM Differentiation in the Works | GenomeWeb

The story has been corrected to reflect the proper name of a firm that three of the founders of Affomix had previously founded. The name of that company is Protometrix.

Antibody firm Affomix, founded about a year ago, is ready to launch a custom antibody service business using a technology that it said significantly improves the affinity and specificity of the antibodies while shortening the production time as compared to other methods such as yeast two-hybrid.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.